Biologically Similar but Competitively Not So? Economic Considerations of IP Litigation Settlements Involving Biosimilars

#172 Biologically Similar but Competitively Not So? Economic Considerations of IP Litigation Settlements Involving Biosimilars

Posted 1 year ago Tagged

Under the U.S. Supreme Court case FTC v. Actavis (2013), antitrust analysis of “reverse settlements” […]

Michael Kades, Director, Competition Policy, Washington Center for Equitable Growth

#76 What’s Ahead in Pharmaceutical Antitrust Enforcement? Taking Stock of Key Pharmaceutical Issues and Enforcement Actions

Posted 3 years ago Tagged

Although there is little question as to the need for affordable, accessible, and high-quality pharmaceuticals, […]